Who
Gavin MacBeath
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, TScan Therapeutics.
In numbers
- Trades disclosed
- 11
- Buys
- 2
- Sells
- 0
- Bought
- $31K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Sep 2021
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,165,000 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,165,000 at $0.00 | filing |
| 3 Jan 2025filed 11 Feb 2025 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 12 Jan 2024filed 11 Feb 2025 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,121,300 at $0.00 | filing |
| 2 Feb 2023filed 6 Feb 2023 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 25 Jul 2022filed 27 Jul 2022 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 18 Jan 2022filed 20 Jan 2022 | TCRX TScan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 21 Sep 2021filed 22 Sep 2021 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Bought | $35357 at $6.19 | filing |
| 20 Sep 2021filed 22 Sep 2021 | TCRX TScan TherapeuticsBiotechnology | SEC FORM 4 Bought | $31K4,943 at $6.22 | filing |
News
No headline names them, or the companies they trade most, lately.